Christos J Petropoulos: Influence Statistics

Christos J Petropoulos

Christos J Petropoulos

From the Division of HIV, Infectious Diseases, and Global Medicine (M.J.P., H.M.S., C.A.F., R.H., V.T., S.G.D.), and Department of Neurology (A.N.N.), University of ...

Christos J Petropoulos: Expert Impact

Concepts for which Christos J Petropoulos has direct influence: Reverse transcriptase , Her2 expression , Drug susceptibility , Human immunodeficiency virus , Immunodeficiency virus , Human immunodeficiency , Replication capacity .

Christos J Petropoulos: KOL impact

Concepts related to the work of other authors for which for which Christos J Petropoulos has influence: Antiretroviral therapy , Hiv infection , Reverse transcriptase , Neutralizing antibodies , Human immunodeficiency virus , Viral load , Resistance mutations .

KOL Resume for Christos J Petropoulos

Year
2022

From the Division of HIV, Infectious Diseases, and Global Medicine (M.J.P., H.M.S., C.A.F., R.H., V.T., S.G.D.), and Department of Neurology (A.N.N.), University of California, San Francisco; Icahn School of Medicine at Mount Sinai (H.H.), New York; Department of Epidemiology and Biostatistics (S.L., S.A.G., J.N.M., J.D.K., D.V.G.), and Division of Experimental Medicine (S.E.M., P.W.H., T.J.H.), University of California, San Francisco; Monogram Biosciences Inc. (A.C., B.C.Y., J.W.W., C.J.P.), South San Francisco, CA; Division of Cardiology (M.S.D., P.Y.H.), Division of Geriatrics (M.G.), Weill Institute for Neurosciences (F.C.C.), Departments of Neurology and Medicine (Infectious Diseases), and Memory and Aging Center (J.H.), Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco.

LabCorp-Monogram Biosciences, South San Francisco, California, USA

Oncology Group, Monogram Biosciences, South San Francisco, United States of America

2021

Monogram Biosciences Inc, South San Francisco, CA, USA

Labcorp, Burlington, NC

2020

Laboratory Corporation of America (LabCorp), South San Francisco, CA, USA.

Monogram Biosciences, San Francisco, CA, USA

2019

Monogram Biosciences, 345 Oyster Point Blvd, 94080, San Francisco, CA, USA

2018

Monogram Biosciences, South San Francisco, CA 94080, USA

2017

Monogram Biosciences, Integrated Oncology, Laboratory Corporation of America® Holdings

2016

Monogram Biosciences, South San Francisco, CA

2015

Monogram Biosciences, South San Francisco, California, United States of America

2014

Monogram Biosciences Inc., 345 Oyster Point Blvd., South San Francisco, CA 94080, USA

2013

Monogram Biosciences, South San Francisco, California 94080, United States

2012

Monogram Biosciences, Inc., South San Francisco, California, USA

2011

Monogram Biosciences, South San Francisco, CA 94080, United States

2010

Department of Oncology, Research and Development, Monogram Biosciences, Inc., South San Francisco, CA 94080, USA

From the *University of California, San Francisco, CA; †San Francisco VA Medical Center, San Francisco, CA; ‡Monogram Biosciences, South San Francisco, CA; §Quest Clinical Research, San Francisco, CA; and ¶Harvard Medical School, Boston, MA.

Monogram Biosciences, South San Francisco, California 94080

2009

Monogram Biosciences, South San Francisco, California 94080.

2008

Monogram Biosciences, South San Francisco, USA

2007

Monogram Biosciences Inc., 345 Oyster Point Boulevard, South San Francisco, California

2006

Monogram BioSciences, Inc., 345 Oyster Point Boulevard, South San Francisco, CA 94080–1913, USA.

ViroLogic Inc., South San Francisco, USA

2005

ViroLogic, Inc., South San Francisco, California 94080

2004

ViroLogic, Inc., South San Francisco, California, 94080

2003

Divisions of Clinical Research and Research & Development, ViroLogic, Inc., San Francisco, California, USA

Department of Research and Development, ViroLogic, Inc., South San Francisco, California 94080

2002

ViroLogic, South San Francisco

2001

ViroLogic, South San Francisco, Calif. (T.W., N.S.H., C.J.P.)

From the Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia, Applied Biosystems, Foster City, ViroLogic Inc., South San Francisco, Californaia, USA, and Alfred Hospital, Prahran, Victoria, Australia.

2000

ViroLogic Inc., South San Francisco, California 94080, and

1999

Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

University of California, San Francisco, San Francisco General Hospital, ViroLogic, Inc., and Gladstone Institute of Virology and Immunology, San Francisco, and Agouron Phamaceuticals, La Jolla, California; Glaxo-Wellcome, Research Triangle Park, North Carolina

1998

ViroLogic, South San Francisco, Calif. (C.J.P., H.T., N.S.H.)

1997

Research Virology Laboratory, Department of Process Sciences, Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080

1996

ABL-Basic Research Program, NCI-Frederick Cancer Research and Developmental Center, Frederick, Maryland 21702-1201, USA.

Genentech Inc. Process Sciences South San Francisco, California 94080

1994

Molecular Virology Laboratory, Genentech, Inc., South San Francisco, California 94080.

Genentech Inc., South San Francisco, CA 94080

1992

ABL-Basic Research Program, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.

1991

Molecular Mechanisms of Carcinogenesis Laboratory, ABL‐Basic Research Program, National Cancer Institute–Frederick Cancer Research and Development Center, Frederick, Maryland

1989

BRI-Basic Research Program, National Cancer Institute-Frederick Cancer Research Facility, Maryland 21701-1013.

1988

National Cancer Institute-Frederick Cancer Research Facility, Maryland 21701-1013.

Prominent publications by Christos J Petropoulos

KOL-Index: 16446 . Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutations K65R and M184V result in changes in susceptibility to several nucleoside and nucleotide RT inhibitors. K65R-containing viruses showed decreases in susceptibility to tenofovir, didanosine (ddI), abacavir, and (-)-beta-D-dioxolane guanosine (DXG; the active metabolite of amdoxovir) but appeared to be ...
Known for Transcriptase Mutations | Replication Capacity | K65r Mutation | Molecular Mechanisms
KOL-Index: 15200 . BACKGROUND: In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown. METHODS: Sixteen patients who had a plasma HIV RNA level of more than 2500 copies per milliliter during combination antiretroviral-drug therapy ...
Known for Drug Therapy | Detectable Viremia | Immunologic Consequences | Cd4 Cell
KOL-Index: 14881 . BACKGROUND: Central nervous system (CNS) exposure to HIV is a universal facet of systemic infection. Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful window into and model of human CNS HIV infection. METHODS: Prospective study of the relationships of CSF to plasma HIV RNA, and the effects of: 1) progression of systemic infection, ...
Known for Hiv Infection | Csf Plasma | Antiretroviral Treatment | Cerebrospinal Fluid
KOL-Index: 14080 . The selection of patients with HER2-positive breast cancer for treatment with trastuzumab is based on the measurement of HER2 protein expression by immunohistochemistry, or the presence of HER2 gene amplification by fluorescence in situ hybridization (FISH). By using multivariate analyses, we investigate the relationship between quantitative measurements of HER2 expression or HER2:HER2 ...
Known for Her2 Expression | Trastuzumab Treatment | Metastatic Breast Cancer | Differential Survival
KOL-Index: 13109 . Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been intensively studied, but we still have a limited appreciation of their neutralization breadth. Using a pseudovirus assay, we evaluated MAbs from clade B-infected donors and a clade B HIV(+) plasma against 93 viruses from ...
Known for Monoclonal Antibodies | Clade Neutralization | Type 1 | Cd4 Binding Site
KOL-Index: 13064 . CONTEXT: Loss of viral suppression in patients infected with human immunodeficiency virus (HIV), who are receiving potent antiretroviral therapy, has been attributed to outgrowth of drug-resistant virus; however, resistance patterns are not well characterized in patients whose protease inhibitor combination therapy fails afterachieving viral suppression. OBJECTIVE: To characterize drug ...
Known for Drug Susceptibility | Viral Rebound | Hiv Infection | Reverse Transcriptase
KOL-Index: 12274 . Acute human immunodeficiency virus (HIV) infection is associated with the rapid development of neutralization escape mutations. The degree to which viral evolution persists in chronic infection has not been well characterized, nor is it clear if all patients develop high-level neutralization antibody escape. We therefore measured neutralizing antibody responses against autologous and ...
Known for Neutralizing Antibody | Heterologous Viruses | Chronic Infection | Autologous Virus
KOL-Index: 12246 . Many studies have demonstrated that the third variable region (V3) of the human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) is a major determinant of coreceptor tropism. Other regions in the surface gp120 subunit of Env can modulate coreceptor tropism in a manner that is not fully understood. In this study, we evaluated the effect of env determinants outside of V3 on ...
Known for Coreceptor Tropism | Envelope Protein | Amino Acid | V3 Sequences
KOL-Index: 12045 . Two amino acids inserted between residues 69 and 70 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are rare mutations that may develop in viruses containing multiple thymidine analog (zidovudine [AZT], stavudine)-associated mutations and that confer high-level resistance to all currently approved chain-terminating nucleoside and nucleotide RT inhibitors (NRTIs). ...
Known for Reverse Transcriptase | Tenofovir Resistance | Molecular Mechanisms | Virus Type
KOL-Index: 11815 . In human immunodeficiency virus type 1 (HIV-1) subtype B, CXCR4 coreceptor use ranges from approximately 20% in early infection to approximately 50% in advanced disease. Coreceptor use by non-subtype B HIV is less well characterized. We studied coreceptor tropism of subtype A and D HIV-1 collected from 68 pregnant, antiretroviral drug-naive Ugandan women (HIVNET 012 trial). None of 33 ...
Known for Coreceptor Tropism | Ccr5 Receptors | Immunodeficiency Virus | Type 1
KOL-Index: 11723 . CONTEXT: Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy. OBJECTIVE: To determine trends in prevalence of HIV-1 drug resistance among recently infected individuals in a geographic area with a high penetration of antiviral treatment. DESIGN, SETTING, AND PATIENTS: Consecutive case series of 225 ...
Known for Infected Persons | Genotypic Resistance | Time Trends | Hiv1 Drug
KOL-Index: 11637 . Anti-human immunodeficiency virus type 1 (HIV-1) antibodies whose binding to gp120 is enhanced by CD4 binding (CD4i antibodies) are generally considered nonneutralizing for primary HIV-1 isolates. However, a novel CD4i-specific Fab fragment, X5, has recently been found to neutralize a wide range of primary isolates. To investigate the precise nature of the extraordinary neutralizing ...
Known for Glycoprotein Gp120 | Primary Isolates | Human Immunodeficiency | Virus Type
KOL-Index: 11310 . The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H and Q148R(H)(K) that reduce susceptibility to the integrase inhibitor raltegravir have been identified in patients failing treatment regimens containing raltegravir. Whether these resistance mutations occur individually or in combination within a single virus genome has not been defined, nor do we fully understand ...
Known for Replication Capacity | Raltegravir Resistance Mutations | Immunodeficiency Virus | Type 1
KOL-Index: 11155 . Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure, and liver cancer. Available antiviral therapies cause severe side effects and are effective only for a subset of patients, though treatment outcomes have recently been improved by the combination therapy now including boceprevir and ...
Known for Molecular Basis | Protease Inhibitors | Resistance Drug | Hepatitis Virus
KOL-Index: 11038 . CONTEXT: The transmission of drug-resistant human immunodeficiency virus (HIV) has been documented, but the prevalence of such transmission is unknown. OBJECTIVE: To assess the spectrum and frequency of antiretroviral susceptibility among subjects with primary HIV infection. DESIGN, SETTING, AND PATIENTS: Retrospective analysis of 141 subjects identified from clinical research centers in 5 ...
Known for Drug Susceptibility | Reverse Transcriptase | Primary Hiv | Patients Resistance

Key People For Reverse Transcriptase

Top KOLs in the world
#1
Stephen H Hughes
reverse transcriptase nonnucleoside inhibitors leukemia virus
#2
Douglas D Richman†
antiretroviral therapy hiv infection human immunodeficiency virus
#3
De Clercq De Clercq
antiviral activity reverse transcriptase human immunodeficiency virus
#4
Edward V Arnold
reverse transcriptase human rhinovirus nonnucleoside inhibitors
#5
Brendan A Larder
reverse transcriptase human immunodeficiency virus antiretroviral therapy
#6
Mark A Wainberg
reverse transcriptase immunodeficiency virus resistance mutations

From the Division of HIV, Infectious Diseases, and Global Medicine (M.J.P., H.M.S., C.A.F., R.H., V.T., S.G.D.), and Department of Neurology (A.N.N.), University of California, San Francisco; Icahn School of Medicine at Mount Sinai (H.H.), New York;